ReviewProstate cancer and prostatic diseases2009
PDE5 inhibitors for LUTS.
Review in Prostate cancer and prostatic diseases, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- The Role of 5-Phosphodiesterase Inhibitors (PDE-5I) in Current Benign Prostatic Hyperplasia Treatment: A Narrative Review.Medicina (Kaunas, Lithuania) · 2024Review
- Risks and side effects in the medical management of benign prostatic hyperplasia.Prostate international · 2024Review
- Heme oxygenase levels and metaflammation in benign prostatic hyperplasia patients.World journal of urology · 2016Article
- The new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase-5 inhibitors.Central European journal of urology · 2014Review
- The use of PDE-5 inhibitors in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.Current urology reports · 2013Review
- Nitric Oxide Synthase is Necessary for Normal Urogenital Development.Andrology : open access · 2013Article
- PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH.Current bladder dysfunction reports · 2013Article
- Urodynamic effects of once-daily tadalafil in men with LUTS secondary to clinical BPH.Current urology reports · 2010Article
- Association of lower urinary tract symptoms and erectile dysfunction: pathophysiological aspects and implications for clinical management.International journal of impotence researchReview
- Predicting erectile dysfunction in sexually active patients seeking prostate health screening: proposal for a multivariable risk stratification.International journal of impotence researchArticle
- Nightly sildenafil use after radical prostatectomy has adverse effects on urinary convalescence: Results from a randomized trial of nightly vs on-demand dosing regimens.Canadian Urological Association journal = Journal de l'Association des urologues du CanadaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To review the current literature regarding the relationship between lower urinary tract symptoms (LUTS) and erectile dysfunction (ED), and the role of phosphodiesterase-5 (PDE5) inhibitors for the treatment of LUTS. Review of recently published (1990-2009) data regarding epidemiologic and pathophysiologic mechanisms are involved in LUTS-ED, focusing on PDE5 inhibitors particularly evidenced from level 1 clinical trials. Search terms included phosphodiesterase inhibitors, nitric oxide, autonomic hyperactivity, Rho-kinase, atherosclerosis, LUTS, benign prostatic hypertrophy, and ED. Results of several epidemiologic studies show a possible causal relationship between LUTS and ED. Four possible mechanisms have been proposed to explain this association. Multiple large clinical trials have shown a benefit in LUTS after PDE5-inhibitors treatment. PDE5 inhibitors show promise as a future treatment for LUTS, either in conjunction with existing therapies or as a primary treatment.
Indexed as
Identifiers
19687801What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.